Compound Might Aid Leukemia Patients Resistant To Gleevec
Scientists have developed a compound that may be able to treat cases of chronic myelogenous leukemia that are resistant to the so-called miracle drug Gleevec.
Human trials could start in as little as six months, said Prem Reddy, senior author of a study appearing in this week's issue of the Proceedings of the National Academy of Sciences.